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Background: Human induced pluripotent stem cell-derived mesenchymal stem cells (hiPSC-MSCs) have emerged
as a promising alternative for stem cell transplantation therapy. Exosomes derived from mesenchymal stem cells
(MSC-Exos) can play important roles in repairing injured tissues. However, to date, no reports have demonstrated
the use of hiPSC-MSC-Exos in cutaneous wound healing, and little is known regarding their underlying mechanisms
in tissue repair.
Methods: hiPSC-MSC-Exos were injected subcutaneously around wound sites in a rat model and the efficacy
of hiPSC-MSC-Exos was assessed by measuring wound closure areas, by histological and immunofluorescence
examinations. We also evaluated the in vitro effects of hiPSC-MSC-Exos on both the proliferation and migration
of human dermal fibroblasts and human umbilical vein endothelial cells (HUVECs) by cell-counting and scratch assays,
respectively. The effects of exosomes on fibroblast collagen and elastin secretion were studied in enzyme-linked
immunosorbent assays and quantitative reverse-transcriptase–polymerase chain reaction (qRT-PCR). In vitro capillary
network formation was determined in tube-formation assays.
Results: Transplanting hiPSC-MSC-Exos to wound sites resulted in accelerated re-epithelialization, reduced scar widths,
and the promotion of collagen maturity. Moreover, hiPSC-MSC-Exos not only promoted the generation of newly
formed vessels, but also accelerated their maturation in wound sites. We found that hiPSC-MSC-Exos stimulated the
proliferation and migration of human dermal fibroblasts and HUVECs in a dose-dependent manner in vitro. Similarly,
Type I, III collagen and elastin secretion and mRNA expression by fibroblasts and tube formation by HUVECs were also
increased with increasing hiPSC-MSC-Exos concentrations.
Conclusions: Our findings suggest that hiPSC-MSC-Exos can facilitate cutaneous wound healing by promoting
collagen synthesis and angiogenesis. These data provide the first evidence for the potential of hiPSC-MSC-Exos
in treating cutaneous wounds.
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The skin is frequently injured by acute and chronic
wounds, such as diabetic skin ulcerations or extensive
burns, which cause physical and mental suffering in
affected individuals, as well as heavy financial burdens at
the familial and societal levels. Although numerous inves-
tigations have focused on expediting the wound healing
process, definitive treatments are currently unavailable.
In recent years, advances in stem cell transplantation
therapy have shown promise in promoting skin-wound
healing. Mesenchymal stem cells (MSCs) and embryonic
stem cells (ESCs) have been most commonly studied,
and they have been effective in promoting wound healing
when injected into wound sites, alone or in combination
with biological materials [1-3].
However, the procedures involved in harvesting MSCs
from adult tissues are invasive and the proliferation and
differentiation capacities of MSCs are limited after sev-
eral passages in culture. Moreover, the proliferation and
differentiation potential of MSCs declines significantly
when age-related disorders occur and with increasing
age [4,5]. The application of ESCs faces substantial eth-
ical and safety hurdles. These factors restrict the clinical
application of MSCs and ESCs. Induced pluripotent stem
cells (iPSCs) are similar to ESCs in terms of morphology,
self-renewal, and differentiation capacity [6,7], and iPSCs
can be generated from any tissue type in the body. While
iPSCs show unlimited growth capacity, are not associated
with ethical concerns, are superior to traditional MSCs
and ESCs, and can serve as an inexhaustible source for
stem cell transplantation therapy, but iPSCs are also
potentially tumorigenic [8]. Mesenchymal stem cells de-
rived from iPSCs (iPSC-MSCs) offer the advantages of
both MSCs and IPSCs. Specifically, abundant MSCs can
be generated from iPSCs, and while iPSC-MSCs can be
passaged >40 times in culture and sustain the self-renewal
capacity characteristic of MSCs [9], they are also no longer
tumorigenic [10,11]. Patient-specific iPSC-MSCs can be
used for autologous transplantation without immuno-
logical rejection and the beneficial effects of iPSC-MSCs
in tissue repair have already been demonstrated [9,12,13].
Despite their apparent advantages, issues of allogeneic and
xenogeneic immunological rejection and chromosomal
variation in cell transplantation therapy still exist [14,15].
Hence, the focus of this study was on developing a strat-
egy to overcome the disadvantages of cell transplantation
therapy.
Recent studies have demonstrated that stem cell trans-
plantation therapy promotes wound healing mainly through
a paracrine mechanism [16-18], and that exosomes play a
major role in this mechanism [19-22]. Exosomes–positive
for CD9, CD63, CD81, are nano-sized extracellular vesicles
(30–100 nm in diameter) generated from many cell types
and tissues. Exosomes, contain proteins, mRNAs, andmiRNAs [23,24], and are formed within endosomal com-
partments and released into the extracellular milieu,
where then play an important role in intercellular commu-
nication [25]. Studies have also indicated that exosomes
derived from MSCs (MSCs-Exos) have promise in tissue
repair therapy [26-28]. Because iPSC-MSCs exert stronger
therapeutic effects in tissue repair than do BMSCs [9,29],
we hypothesized that iPSC-MSC-Exos may also promote
tissue repair during wound healing.
In the present study, we verified the therapeutic effects
of hiPSC-MSC-Exos in cutaneous wound healing. Consist-
ent with our hypothesis, we found that hiPSC-MSC-Exos
significantly enhanced wound healing, collagen synthesis,
and the genesis of newly formed vessels and mature
vessels in wound sites. Our in vitro studies showed that
hiPSC-MSC-Exos can promote the proliferation and mi-
gration of human fibroblasts and HUVECs, enhance fibro-
blasts collagen and elastin secretion, and increase tube
formation by HUVECs. These data show for the first time
that hiPSC-MSC-Exos facilitate cutaneous wound healing
by promoting collagen synthesis and angiogenesis.
Methods
Derivation and characterization of hiPSC-MSCs
Three human iPSC cell lines were used to generate MSCs.
The first human iPSCs line (iPS-S-01) was provided by the
Institute of Biochemistry and Cell Biology of the Chinese
Academy of Sciences, with permission from Liao and Xiao
[30]. Two additional iPSC lines, namely iPSCs-(C1P33)
and iPSCs-(PCKDSF001C1), were provided by the South
China Institute for Stem Cell Biology and Regenerative
Medicine Group of the Chinese Academy of Sciences,
with permission from Professor Pei [31]. After 5 days in
culture, the mTESR1 (Stemcell) was replaced with MSC
medium, prepared by supplementing Dulbecco’s Modified
Eagle Medium with 10% FBS, 1% penicillin/streptomycin,
2 mM L-glutamine, and 0.1 mM non-essential amino
acids (all supplements from Gibco), and the medium was
subsequently changed every 2 days [32]. At 2 weeks cul-
tured in MSC medium, cells were harvested and expanded
in 0.1% gelatin-coated dishes with MSC medium. Cells
were continually passaged every 5–7 days until they devel-
oped a homogeneous fibroblastic morphology, after which
they were evaluated in terms of MSC phenotype charac-
teristics and differentiation potentials.
Surface antigens of hiPSC-MSCs were analysed by
flow cytometry. Cells at Passage 4 were harvested using
trypsin-EDTA (Invitrogen) and incubated for 30 min
with 3% Bovine Serum Albumin (BSA, Gibco) in PBS to
block nonspecific antigen binding. Cells were next incu-
bated with antibodies (Becton Dickinson) recognizing
characteristic human MSC surface markers, including:
phycoerythrin (PE)-conjugated anti-CD29, PE-conjugated
anti-CD73, fluorescein isothiocyanate-conjugated anti-
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isothiocyanate-conjugated anti-CD45, and PE-conjugated
HLA-DR. Surface antigens were analysed using a Guava
easyCyte™ flow cytometer.
The functional differentiation of hiPSC-MSCs into
osteogenic, chondrogenic, and adipogenic lineages was
tested in specific culture media. To study osteogenesis,
hiPSC-MSCs were incubated in osteogenic medium
(Gibco) for 3 weeks and then fixed in 4% paraformalde-
hyde for 30 min at room temperature (RT). Calcified
matrix deposition was detected by Alizarin Red staining.
Chondrogenesis was studied by seeding hiPSC-MSCs in
chondrogenic medium (Gibco) and maintaining them
for 4 weeks in culture. The cells were then fixed in 4%
paraformaldehyde for 30 min at RT, and proteoglycans
were detected by Alcian Blue staining. For adipogenesis
studies, hiPSC-MSCs were incubated in adipogenic
medium (Gibco) for 2 weeks, fixed in 4% paraformalde-
hyde for 30 min at RT, and lipid vacuoles were detected
by Oil Red O staining. Tri-lineage differentiation poten-
tial was confirmed by qRT-PCR measurement of gene
expression levels of markers associated with osteo-,
chondro-, and adipogenic differentiation after 7 days in
culture with osteo-, chondro-, and adipogenic mediun.
The total RNA was isolated using Trizol (Invitrogen),
and 1 μg of RNA in a final reaction volume of 20 μl was
then reversed-transcribed into complementary DNA
(cDNA) using the PrimeScript 1st Strand cDNA Synthesis
kit (TaKaRa) according to the manufacturer’s instructions.
qRT-PCR was performed using SYBR Premix Ex Taq
(Takara) in combination with an ABI 7500 Real-Time
PCR System (Applied Biosystems). Threshold cycles of
primer probes were normalized to the housekeeping gene
GAPDH and translated to relative values. The primers are
synthesized as follows: OCN: forward, 5′-CCCCCTCTA
GCCTAGGACC-3′, and reverse, 5′-ACCAGGTAATGC
CAGTTTGC-3′; SOX 9: forward, 5′-AGCGCCCCCACT
TTTGCTCT-3′, and reverse, 5′-GCTCGCCCTTGGGG
AACGTG-3′; LPL: forward, 5′-TGGAGGTACTTTTC
AGCCAGGAT-3′, and reverse, 5′-CGTGGGAGCAC
TTCACTAGCT-3′; GAPDH: forward, 5′-ATCCCATCA
CCATCTTCC-3′, and reverse, 5′-GAGTCCTTCCACG
ATACCA-3′.
Isolation and identification of hiPSC-MSC-Exos
After hiPSC-MSCs reached ~80% confluency, the culture
medium was replaced with MesenGro hMSC medium
(StemRD), and the cells were cultured for an additional
48 h. Conditioned medium (CM) was collected and
exosomes were isolated as described previously [33,34].
Briefly, the CM was centrifuged sequentially at 300 × g
for 10 min and then at 2000 × g for 10 min. Next, the
cellular debris in CM supernatants was removed by
0.22-μm filtration, and supernatants were ultracentrifugedat 100,000 × g for 2 h. Pelleted exosomes were resus-
pended in PBS, centrifuged at 4000 × g until the volume in
the upper compartment was reduced to approximately
200 μL. The total protein concentration in exosomes was
quantitated using the Micro Bicinchoninic Acid (BCA)
Protein Assay Kit (Pierce), according to the manufacturer’s
recommended protocol. All procedures were performed
at 4°C. Exosome morphologies were observed using a
Hitachi H-7650 transmission electron microscope (TEM;
Hitachi). Antibodies against the CD9 (1:500; Bioworld),
CD63 (1:1000; Bioworld), and CD81 (1:1000; Epitomics)
proteins were used to analyse the incorporation of each
protein into exosomes in western blots.
Rat skin wound model and treatment
All procedures were approved by the Animal Research
Committee of the Sixth People’s Hospital at the Shanghai
Jiao Tong University. Adult male SD rats weighing 250–
300 g were used in this study. These rats were anesthetized
by intraperitoneal injection of 50 mg/kg pentobarbital.
After shaving the rats, 3 wounds (18 mm in diameter) were
created on the dorsal skin. Rats were randomly assigned
to 3 different treatment groups, which were subcutane-
ously injected at wound sites with PBS (untreated group),
MesenGro hMSC medium (control group), or hiPSC-
MSC-Exos (experimental group). Rats in the respective
groups were injected with 160 μL of PBS, MesenGro hMSC
medium, or hiPSC-MSC-Exos (160 μg) in PBS around the
wounds at 4 injection sites, and 40 μL of matching solution
(PBS, medium, or exosomes (40 μg)) was applied to the
wound beds of the respective groups. Six wounds per
treatment were studied by histopathological analysis at
Day 7 and 14 post-wounding. Wound-size reduction was
calculated using the equation: wound-size reduction (%) =
(AO – At)/AO × 100, where AO is the initial wound area,
and At is the wound area at Day 7 or 14 post-wounding.
Histology
For histological analyses, the excised skin from wound sites
was fixed in 10% formalin, dehydrated with a graded-
alcohol series, embedded in paraffin, and sectioned perpen-
dicularly to the wound surface into 4-μm-thick sections.
Hematoxylin and eosin (H&E) staining was used for histo-
logical observations. The percentage of re-epithelisation
(E%) was calculated using the equation: E% =WN/WO×
100, where WO is the original wound area and WN is the
length of newly generated epithelium across the surface of
the wound. Masson’s trichrome staining was used to deter-
mine the degree of collagen maturity.
Immunofluorescence study
CD31 and alpha smooth muscle actin (α-SMA) were de-
tected by immunofluorescence to study exosome-induced
angiogenesis during the wound healing process. For
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wound sites was fixed in 4% paraformaldehyde, dehy-
drated in 30% sucrose solution, embedded in OCT, and
sectioned perpendicularly to the wound surface into
4-μm-thick sections. Tissue sections were blocked in
1% BSA for 30 min at RT, incubated with rabbit anti-
CD31 (1:100, Abcam) and mouse anti-α-SMA (1:50,
Abcam) antibodies overnight at 4°C. Subsequently, tis-
sue sections were stained with secondary Alexa-Fluor
594-conjugated goat anti-rabbit and Alexa-Fluor 488-
conjugated goat anti-mouse antibodies (1:200) and coun-
terstained with DAPI. Images were acquired with an
Olympus IX81 microscope. The newly formed vessels
were indicated by CD31 positive staining, mature vessels
were detected as CD31 and α-SMA double-positive vascu-
lar structures. The number of newly formed vessels and
mature vessels were determined by counting in five
random fields per section between wound edges using
Image-Pro Plus 6.
Treatment of fibroblasts with hiPSC-MSC-Exos in vitro
Human fibroblasts were obtained from 4 donors with
written informed consent. The effects of hiPSC-MSC-
Exos on the proliferation of human fibroblasts (passage
6–9) were evaluated using the Cell Counting Kit-8
(CCK-8) (Dojindo) according to manufacturer's ins-
tructions. Fibroblasts were seeded into 96-well plates at
5 × 103 cells/well. After 12 h, 0, 50, or 100 μg/mL exo-
somes was added to the wells. The medium was changed
daily for 5 days, using fresh medium containing the
same exosomes concentrations. Cell proliferation curves
were constructed by measuring amount of formazan dye
generated by cellular dehydrogenase activity with a mi-
croplate reader at a wavelength of 450 nm.
The effects of exosomes on fibroblasts migration were
evaluated in scratch assays, as described previously [35].
Briefly, 2 × 105 cells/well were seeded into 6-well plates
and incubated for 6 h. Then, the confluent layer of cells
was scratched using a sterile 20–200 μl pipette tip. After
washing the cells with PBS, 0, 50, or 100 μg/mL exo-
somes was added. Images were recorded at 0, 12, and
24 h after the monolayers were scratched. Scratched
areas were measured using the Image-Pro Plus 6.0 soft-
ware. The effects of exosomes on fibroblasts migration
were evaluated in cell responses level by western blot
measurement of fibronectin (Santa Cruz Biotechnology)
protein levels at 24 h. The total cellular proteins were
first extracted and the cell lysates were cleared by centri-
fugation at 4°C and 12,000 rpm for 15 min. The protein
concentrations of the lysates were quantified using a
BCA assay Kit. The cell proteins were separated by
standard sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to polyvinyli-
dene difluoride (PVDF) membranes. After incubation in5% BSA blocking solution for 1 h, the membranes were
incubated overnight at 4°C with anti-fibronectin anti-
body (Abcam). The membranes were then washed three
times with PBS-Tween-20 and incubated with horserad-
ish peroxidase (HPR)-conjugated secondary antibodies at
37°C. The immunoreactive bands were visualized using
the ECL chemiluminescence reagent (Millipore).
The effects of exosomes on fibroblasts collagen and
elastin secretion were evaluated with an enzyme-linked
immune sorbent assay (ELISA) kit (Wes tang Bio-tech)
and qRT-PCR. Fibroblasts (2 × 105 cells/well) were seeded
into 6-well plates, after which 0, 50, or 100 μg/mL
exosomes were added. At Days 1, 2, and 3 in culture, the
supernatants were collected and Type I, III collagen and
elastin levels were detected using the ELISA kit, according
to manufacturer's instructions. The mRNA levels of Type
I, III collagen and elastin were examined by qRT-PCR.
Threshold cycles of primer probes were normalized to the
housekeeping gene GAPDH and translated to relative
values. The primer is synthesized as follows: Type I colla-
gen: forward, 5′-AGGACAAGAGGCATGTCTGGTT-3′,
and reverse, 5′-TTGCAGTGGTAGGTGATGTTCTG-3′;
Type III collagen: forward, 5′-TGGATCAGATGGTCTTC
CA-3′, and reverse, 5′-TCTCCATAATACGGGGCAA-3′;
GAPDH: forward, 5′-ATCCCATCACCATCTTCC-3′, and
reverse, 5′-GAGTCCTTCCACGATACCA-3′.
Treatment of HUVECs with hiPSC-MSC-Exos in vitro
Human umbilical cords were harvested after obtaining
informed consent from donors. The effects of exosomes
on HUVECs proliferation and migration were evaluated
as described above. In vitro capillary-network formation
in Matrigel was monitored by performing tube-formation
assays. Culture plates (24-well) were pre-coated with
Matrigel, and 5 × 104 cells/well were seeded in M200
medium containing 50 or 100 μg/mL of hiPSC-MSC-Exos
and cultured for 4, 6, or 18 h. Separate wells of control
cells were grown in M200 medium alone. At each time
point, the number of total branch points and tubule
lengths in 5 randomly chosen fields were quantified.
Statistical analysis
All data are shown as mean ± standard deviation (SD). Dif-
ferences between groups were assessed by one-way analysis
of variance (ANOVA) with GraphPad Prism software.
P values < 0.05 were considered statistically significant.
Results
Characterization of hiPSC-MSCs and hiPSC-MSC-Exos
Using a modified one-step induction protocol, we success-
fully derived human MSCs from 3 different iPSC cell lines.
Under the induction conditions used, the hiPSCs showed
a tendency to form packed clones with decreased nuclear:
cytoplasmic volume ratios, and formed a monolayer with
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colonies after culture in MSC medium for a few days.
After culturing cells on gelatin-coated dishes for 14 days,
they were continually passaged when reached to 90% con-
fluence until homogeneous fibroblastic morphologies were
observed (Figure 1A). The differentiation of hiPSCs into
MSCs was assessed by staining cells with MSC-markers
and subsequent analysis by flow cytometry. MSCs were
identified as cells positive for CD29, CD73, and CD90 and
negative for CD34, CD45, and HLA-DR (Figure 1B).
Tri-lineage MSC differentiation experiments were per-
formed to assess the multipotency of the derived cells.
Osteogenesis was studied by measuring the formation of
amorphous calcium mineral deposits by Alizarin Red
staining after 3 weeks of differentiation (Figure 1Ca).
Chondrogenesis was studied by determining the presence
of polysaccharides and proteoglycans by Alcian Blue
staining after 4 weeks of differentiation (Figure 1Cb).
Adipogenesis was studied by measuring the formation
of small cytoplasmic lipid droplets by Oil Red O staining
after 2 weeks of differentiation (Figure 1Cc). The osteo-,
chondro-, and adipogenic differentiation-related genes
analysis demonstrated that the gene expression of OCN
(Figure 1Cd), Sox9 (Figure 1Ce), and LPL (Figure 1Cf)
were upregulated in induced iPSC-MSCs, respectively.
These results suggest that the derived hiPSC-MSCs
possessed MSC properties and multipotency.
In TEM experiments with hiPSC-MSC-Exos, we ob-
served spheroidal microvesicles that were 30–100 nm in
diameter (Figure 1D), indicating the presence of exo-
somes. Western blotting analyses indicated that the
hiPSC-MSC-Exos expressed exosomal markers, such as
the CD9, CD63, and CD81 proteins (Figure 1E).
hiPSC-MSC-Exos promote cutaneous wound healing in rats
SD rats were anesthetized and 3 wound sites were created
in their dorsal skin areas. We evaluated wound healing in
3 groups of animals that were treated with PBS (untreated
group), MesenGro hMSC medium (control group), or
hiPSC-MSC-Exos (experimental group) in and around the
wound sites. Rats treated with hiPSC-MSC-Exos showed
greater wound closure than observed in the control and
untreated groups at Days 4, 7, and 14 post-wounding
(Figure 2A, B).
Reduced scar widths and increased collagen maturity
are parameters used to assess the degree of wound heal-
ing. As shown in Figure 3A–D, hiPSC-MSC-Exos treat-
ment significantly enhanced re-epithelialization compared
to that observed in the control and untreated groups. The
narrowest scar widths and largest collagen deposition
areas were observed in the hiPSC-MSC-Exos group at
Days 14 post-wounding, compared to the control and
untreated groups. In addition, the collagen fibres in
hiPSC-MSC-Exos group showed no loss of periodicity atDay 14. We also observed increased formation of seba-
ceous glands and hair follicles in hiPSC-MSC-Exos group,
relative to the untreated and control groups.
Vascularization of newly formed tissues is an essential
step in the wound-healing process. Newly formed vessels
and mature vessels at wound sites were characterized by
CD31 staining (Figure 4A) and co-staining against CD31
and α-SMA (Figure 4C), from which average vessel dens-
ities and the number of mature vessels were quantified
(Figure 4B, D). These data showed that the number of
newly formed vessels and mature vessels both increased
along during the healing process for all groups. The
hiPSC-MSC-Exos group showed the highest vessel
densities and numbers of mature vessels at Day 7 and
14, compared with the control and untreated groups.hiPSC-MSC-Exos promote proliferation, migration and
collagen, elastin secretion of human fibroblasts in vitro
Because we observed enhanced collagen synthesis in wound
sites treated with hiPSC-MSC-Exos, we next analysed
the underlying mechanism in vitro with primary fibro-
blasts. Figure 5D demonstrates that fibroblast proliferation
increased substantially in the presence of exosomes in a
dose-dependent manner.
Compared to control cells, the migration of fibroblasts
into scratched areas of monolayers in the presence of
50 μg/mL hiPSC-MSC-Exos increased by 2.3-fold and
1.8-fold after 12 and 24 h, respectively. Similarly, 3.0-fold
and 2.1-fold increases in fibroblast migration rates were
observed in the presence of 100 μg/mL hiPSC-MSC-
Exos after12 and 24 h, respectively, relative to control
cells (Figure 5A, B). hiPSC-MSC-Exos can enhance the
protein expression of fibronectin in fibroblasts in a dose-
dependent manner (Figure 5C).
Figure 5E-G demonstrate that Type I, III collagen and
elastin secretion increased in the presence of hiPSC-
MSC-Exos at 3 time points in a dose-dependent manner,
and the mRNA levels of Type I, III collagen and elastin
were also enhanced significantly in a dose-dependent
manner (Figure 5H-I). Collectively, these results indicate
hiPSC-MSC-Exos can promote proliferation, migration,
and collagen secretion of human fibroblasts in vitro.hiPSC-MSC-Exos promote proliferation, migration and
tube formation of HUVECs in vitro
Because enhanced vascularization was also observed
in the wound site, we next treated HUVECs with
hiPSC-MSC-Exos in vitro to gain insight into the po-
tential mechanism involved. Figure 6C demonstrates
that HUVECs proliferation was substantially increased
in the presence of exosomes at all time points studied,
with the highest proliferation observed in the presence
of 100 μg/mL exosomes.
Figure 1 (See legend on next page.)
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Figure 2 Rats macroscopic appearances of cutaneous wounds treated with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos. (A) Gross
view of wounds treated with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos at 4, 7, and 14 days. (B) The effects of treatment with PBS, MesenGro
hMSC medium, or hiPSC-MSC-Exos on wound closure at 4, 7, and 14 days. *P < 0.05.
(See figure on previous page.)
Figure 1 Characterization of human induced pluripotent stem cell-derived mesenchymal stem cells (hiPSC-MSCs) and hiPSC-MSC-derived
exosomes (hiPSC-MSC-Exos). (A) Light microscopy images demonstrating morphological changes occurring during hiPSCs differentiation into
fibroblast-like cells. (a) Representative cell morphology of hiPSCs before differentiation. (b) Intermediate phase of differentiating the hiPSCs into MSCs.
(c) Typical fibroblast-like morphology of cells. (B) Flow cytometric analysis of the surface markers in hiPSC-MSCs. (C) Assessment of the tri-lineage
differentiation capacity of iPSC-MSC-like cells. (a) Alizarin Red staining for osteocytes after 3 weeks in culture with osteogenic medium. (b) Alcian
Blue staining for chondrocytes after 4 weeks in culture with chondrogenic medium. (c) Oil Red O staining for adipocytes after 2 weeks in culture
with adipogenic medium. The qRT-PCR results for OCN (d), Sox9 (e), and LPL (f) after 7 days in culture with osteo-, chondro-, and adipogenic mediun.
(D) Transmission electron microscope images of hiPSC-MSC-Exos morphology. Scale bars = 100 nm and 50 nm, respectively. (E) Detection of CD9,
CD63, and CD81 incorporation into hiPSC-MSC-Exos by western blotting.
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Figure 3 Rats histological analyses of cutaneous wounds treated with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos. (A) H&E staining
of wound sections following treatment with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos at 14 days post-wounding. The double-headed arrows
indicate the edges of the scar. The effects of PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos on wound re-epithelialization (B) and scar widths
(C) at 14 days post-wounding. (D) Evaluation of collagen maturity by Masson’s trichrome staining of wounds following treatment with PBS, MesenGro
hMSC medium, or hiPSC-MSC-Exos at 14 days post-wounding. Scale bar = 500 μm. *P < 0.05; Ep, Epithelium; F, Follicle.
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Figure 4 Immunofluorescence analyses of newly formed vessels and mature vessels. (A) CD31 (red arrows) Immunofluorescence staining of
wound sections treated with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos at 7 and 14 days post-wounding. Scale bar = 50 μm. (B) Enumeration
of newly formed vessels in wounds after treatment with PBS, MesenGro hMSC medium, or hiPSC-MSC-Exos at 7 and 14 days post-wounding. (C)
Immunofluorescent triple staining of wound sections treated with PBS, MesenGro hMSC medium or hiPSC-MSC-Exos at 7 and 14 days post-wounding.
Endothelial cells (CD31), smooth muscle cells (α-SMA), and cell nuclei (DAPI) fluoresced with red, green, and blue colours, respectively. Mature vessels
(green arrows) were dually positive for CD31 and α-SMA. Scale bar = 50 μm. (D) Enumeration of mature vessels in wounds after treatment with PBS,
MesenGro hMSC medium, or hiPSC-MSC-Exos at 7 and 14 days post-wounding. *P < 0.05.
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somes increased by 2.5-fold and 1.9-fold after 12 and
24 h in culture, respectively, and by 3.0-fold and 2.0-fold
at the same time points in the presence of 100 μg/mL
exosomes (Figure 6A, B).
Tubule lengths and branch points were counted after
HUVECs began forming capillary tubes. As shown in
Figure 7, hiPSC-MSC-Exos markedly enhanced tube
formation at 4, 6, and 18 h compared to control cells,
with the highest concentration (100 μg/mL) showing the
strongest effect. Although the mesh-like structure began
dissociating after 18 h in culture, the tubule lengths and
degree of branching observed in exosomes-treated cells
were enhanced relative to control cells. Collectively, thesedata indicate that hiPSC-MSC-Exos can promote prolifer-
ation, migration, and tube formation of HUVECs in vitro.
Discussion
In the present study, we investigated whether hiPSC-
MSC-Exos can exert therapeutic effects in a cutaneous
injury model and explored the underlying mechanisms
involved. Our findings demonstrated for the first time
that hiPSC-MSC-Exos significantly promote cutaneous
wound healing, collagen synthesis, and vascularisation at
wound sites in a rat full-thickness skin defect model.
Further analysis in vitro indicated that hiPSC-MSC-Exos
can promote collagen synthesis in fibroblasts and angio-
genesis in HUVECs directly.
Figure 5 (See legend on next page.)
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Figure 5 The effects of exosomes on the proliferation, migration, and collagen, elastin secretion of human fibroblasts. The light microscopy
images (A) and migration rates (B) of human fibroblasts into scratch sites following growth in MesenGro hMSC medium containing 0, 50, or 100 μg/
mL hiPSC-MSC-Exos for 12 or 24 h. Scale bar = 250 μm. (C) Fibronectin protein expression of human fibroblasts treated with MesenGro hMSC medium
containing 0, 50, or 100 μg/mL hiPSC-MSC-Exos for 24 h. (D) Human fibroblasts proliferation after growth in MesenGro hMSC medium containing 0,
50, or 100 μg/mL hiPSC-MSC-Exos was detected with a CCK-8 kit over 5 days. Secretion of Col I (E), III (F) and elastin (G) by human fibroblasts after
growth in MesenGro hMSC medium containing 0, 50, or 100 μg/mL hiPSC-MSC-Exos over 3 days. (G) The Col I (H), III (I) and elastin (J) mRNA
expression of human fibroblasts treated with MesenGro hMSC medium containing 0, 50, or 100 μg/mL hiPSC-MSC-Exos over 3 days. *P < 0.05.
Zhang et al. Journal of Translational Medicine  (2015) 13:49 Page 11 of 14It has been suggested that the main underlying mech-
anism of stem cell transplantation therapy is likely indir-
ect and depends on the paracrine activity of stem cells.
Recent studies showed that the exosomes, secreted by
cells, strongly contribute to the paracrine effects of stemFigure 6 The effects of exosomes on HUVECs proliferation and migra
HUVECs into the scratched area of monolayers following growth in M200 m
Scale bar = 250 μm. (C) The proliferation of HUVECs grown in M200 contain
using a cell-counting kit.*P < 0.05.cells. Thus, we hypothesized that if the benefits of stem
cell transplantation therapy are mediated by exosomes,
then direct treatment with exosomes may overcome the
limitations and risks associated with stem cell trans-
plantation therapy. Previous studies also demonstratedtion. The light microscopy images (A) and migration rates (B) of
edium containing 0, 50, or 100 μg/mL hiPSC-MSC-Exos for 12 or 24 h.
ing 0, 50, or 100 μg/mL hiPSC-MSC-Exos was detected over 5 days,
Figure 7 The effects of exosomes on tube formation by HUVECs. (A) HUVECs tube formation was studied by growing cells in Matrigel in
M200 medium containing 0, 50, or 100 μg/mL hiPSC-MSC-Exos. Scale bar = 250 μm. Total tube lengths (B) and branch points (C) of HUVECs
following growth in M200 medium containing 0, 50, or, 100 μg/mL hiPSC-MSC-Exos for 4, 6, or 18 h. * P < 0.05.
Zhang et al. Journal of Translational Medicine  (2015) 13:49 Page 12 of 14that human MSC-derived exosomes do not contain
MHC class I or II proteins and thus, their application to
non-immune-compatible animals does not induce overt
immune reactions [36-38], making them suitable for use
in allogeneic or xenogeneic recipients. iPSC-MSCs have
emerged as an alternative resource for stem cell trans-
plantation therapy. Our study demonstrated that hiPSC-
MSCs display MSC-like properties and multipotency.
Previous studies have shown that iPSC-MSCs may be
produced abundantly, have a strong capacity for self-
renewal, and can attenuate tissue ischemia for an im-
proved therapeutic effect compared to adult bone marrow
mesenchymal stem cells [9]. Thus, in the present study,
exosomes derived from hiPSC-MSCs were first adopted toevaluate their effects in cutaneous wound healing in a rat
full-thickness skin defect model.
It was clearly observed that the application of exo-
somes greatly increased re-epithelization and collagen
deposition at wound sites, the nascent collagen fibrils
also showed no loss of periodicity. Meanwhile, exosomes
not only promoted the generation of newly formed
vessels, but also accelerated their maturation at wound
sites. The encouraging results suggested that hiPSC-
MSC-Exos have similar reparative properties as MSCs in
tissue repair. hiPSC-MSC-Exos appear to be a superior
candidate for treating cutaneous wound healing, that
might overcome the obstacles and risks associated with
stem cell transplantation therapy.
Zhang et al. Journal of Translational Medicine  (2015) 13:49 Page 13 of 14The formation of granulation tissues is a major deter-
minant in wound healing, providing a scaffold for the
assembly of neighbouring cells at wound margins, con-
tributing to wound closure. Fibroblasts are the main cell
types comprising granulation tissue. Fibroblasts are pre-
sent in the dermis and proliferate rapidly and migrate to
wound sites [39,40], where they can secrete Type I and III
collagens and elastin, which are the central components
of the extracellular matrix. Studies have demonstrated
that MSCs can promote the proliferation, migration, and
collagen secretion of fibroblasts through a paracrine
mechanism [41]. We showed that hiPSC-MSC-Exos stim-
ulated the proliferation and migration of human dermal
fibroblasts in a dose-dependent manner in vitro, and that
Type I, III collagen and elastin secretion was increased
with increasing hiPSC-MSC-Exos concentrations. Extra-
cellular matrix (ECM) is comprised of various substances
that promote the migration of fibroblasts (fibronectin)
and provide tissue strength and resiliency (collagen and
elastin). The effects of hiPSC-MSC-Exos on fibroblasts
migration were confirmed in cell responses level by west-
ern blot measurement of fibronectin protein levels. These
factors may contribute to wound contraction and collagen
maturation during cutaneous wound healing. Angiogen-
esis is also known to play a critical role in the cutaneous
wound-healing process and is required for granulation
tissue formation. Previous studies showed that BMSCs-
derived exosomes can significantly increase the prolifera-
tion, migration, and tube formation ability of HUVECs
[42] and that exosomes are potentially useful in treating
certain ischemic diseases. However, no reports have thus
far described the application of hiPSC-MSC-Exos incuta-
neous wound healing. Our in vitro experimental results
confirmed that hiPSC-MSC-Exos can increase prolifera-
tion, migration, and tube formation of HUVECs in a dose-
dependent manner. These data indicate that the formation
of nascent and mature vessels during cutaneous wound
healing may be due to the pro-angiogenic effect of hiPSC-
MSC-Exos.
Conclusion
We demonstrated that hiPSC-MSC-Exos exert beneficial
effects on granulation tissue formation and angiogenesis,
which are two critical phases of the wound-healing
process, and that hiPSC-MSC-Exos facilitated a signifi-
cant therapeutic effect during cutaneous wound healing.
Our findings suggest that hiPSC-MSC-Exos may be used
as therapeutic tools in cutaneous wound healing.
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